Navigation Links
Pneumatic Armband

ProductsPneumatic Armband
Company Aircast
Item Pneumatic Armband
Features 
  • Focused compression for less constriction
  • Breathable material enhances comfort and wearability
  • Simple, effective design makes it easy to apply
  • One size fits most for reduced inventory requirements
  • Indications: epicondylitis
    • Description Innovative Aircast aircell technology enables the Pneumatic Armband to focus compression where it counts! Using a single pre-inflated aircell, the Armband concentrates compression directly on the extensor muscle, not around the arm, for more support and less constriction. Designed for comfort and versatility, the Armband is designed to conform to the arm's tapered contour and comfortably cushions the sensitive injured muscle. The Pneumatic Armband is available in beige or black.
    Info Aircast
    Customer Service: (800) 526-8785
    Web site: http://www.aircast.com/

    Related medicine products :

    1. SCD Sequential Compression System Intermittent Pneumatic Compression
    2. PneumaticWalker™ Diabetic System
    3. PneumaticWalker™
    4. Series 1000 Pneumatic Modular Instrument System
    5. Pneumatic Motor Module w/ Hand Throttle
    6. Pneumatic Motor Module, Throttleless
    7. Small Bone Pneumatic Power System
    8. Throttless Pneumatic High Speed Drill
    9. Pneumatic High Speed Drill
    10. Orthotrac Pneumatic Vest
    11. 3.5V Pneumatic Otoscope
    The dual-electrode SPL defibrillator lead features a patented coiled-coil electrode design, offering the flexibility and maneuverability of a pacemaker lead. Designed for the physician who prefers a
    TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol
    The Livewire steerable electrophysiology catheter is uniquely designed with an ergonomic handle and patented steering mechanism to provide smooth, precise catheter tip movement, even during lengthy e
    ...ar-spaced electrodes along a circular tip, providi...ial fibrillation procedures. High resolution mappi...npointing of pulmonary vein potentials than with 1...iency in the catheter-based management of atrial f...
    Medicine Products:
    (Date:5/16/2008)...sents Urban Health Institute with 10,000 Sensual O...rg at Playboy Mansion Fundraiser, LOS ANGELES, Ma...ip-hop,and R & B artist J Kwon known best for his ...ll be presenting the Urban Health Institute (UHI) ... over $50,000. The donation is,being made to promo...
    (Date:5/16/2008)...docs determine who would benefit most from chemo a... 16 (HealthDay News) -- A panel of 15 genes may he...mall cell lung cancer will experience a recurrence...y, a new study shows. , By extension, the same... less aggressive forms of the cancer who would be ...
    (Date:5/16/2008)...TON, May 16 /PRNewswire-USNewswire/ -- As tropical...e Irrawaddy delta, survivors of,Cyclone Nargis are... Many,survivors still need assistance, as exposure... an increasingly dire situation., "The people liv...,recover from this disaster and get back on their ...
    (Date:5/16/2008)...h Funding Per Death Drops More in 2007, WASHINGTO...ncer causes,one in three cancer deaths, the Nation... its $4.8 billion budget in lung cancer research i...Lung Cancer Alliance (LCA) today., The two other ...programs -- Centers for Disease Control and Preven...
    Breaking Medicine News(10 mins):Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Lung Cancer Still Lowest in Federal Funding 2
    ...o a better job of keeping metabolism on track when...ht be helping people keep the pounds off for good,...such as white bread, refined breakfast cereals, an...ing a quick rise in blood sugar and insulin. This ...
    ...ecent study researchers now say that the antidepre...a higher risk // of being admitted to a hospital ...rom 1992 to 2000 on over 64,000 new antidepressant...otonin reuptake inhibition levels on the risk for ...
    ...hours does not only cause fatigue but can also be ... on an airplane for several// hours can cause deep...in which blood clots form in the leg or pelvic vei...with health conditions that promote clotting, such...
    ...f the knee is very common, affecting almost one-te...is an incurable illness //, so treatment is aimed ...hy acupuncture was studied. Acupuncture in additio... is more effective than drug treatment alone, show...
    Other Medicine News:
    (Date:5/15/2008)...ase II Data Presented at ASCO Showed Acceptable To... of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N.J...otherapeutic agent eribulin mesylate (E7389) demon...n of women with locally advanced or metastatic,bre... Phase II clinical,trial. The study also suggests ...
    (Date:5/15/2008)...BRIDGEWATER, N.J., May 15 /...ounced today that findings from the,landmark ATHEN...l therapy,for the treatment of patients with atria...sk of cardiovascular hospitalizations or death fro...0.00000002), meeting the study,primary endpoint. T...
    (Date:5/15/2008)...BONITA SPRINGS, Fla., May 15 /- Tigri...ion of a Cooperative Research and,Development Agre...NCI) to,collaborate on clinical and preclinical de... Phase I development. AFP-464 is converted to,meta... p53 activation and,apoptosis., This is part of a...
    (Date:5/15/2008)...Randomized TRIAS HR Pilot Study Compares Genous, B...Taxus(R), Other Presentations Focus on Real-World ...th AMI, Those Who Could Not Tolerate Dual-Antiplat...ELONA, Spain, May 15 /- OrbusNeich to...tions in a symposium at EuroPCR 2008,support the u...
    Breaking Medicine Technology:Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4Alcons PATANASE 28R 29 Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms 16920 1Alcons PATANASE 28R 29 Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms 16920 2Alcons PATANASE 28R 29 Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms 16920 3Alcons PATANASE 28R 29 Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms 16920 4Press Preview to Unveil Miracle Manny 16916 1Susan Byrne joins GHG Grey Healthcare Group as EVP Strategy and Business Development Europe a Newly Created Position 16911 1Susan Byrne joins GHG Grey Healthcare Group as EVP Strategy and Business Development Europe a Newly Created Position 16911 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease 4627 1Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease 4627 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease 4627 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease 4627 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease 4627 5
    ... 2007 /PRNewswire-FirstCall/ --,Lexicon Pharmaceut... findings from a joint research project with scien...PA. Together with David L.,Wiest, Ph.D., Lexicon r...role for ribosomal protein L22 (Rpl22) in the,deve... published in,the June issue of the journal Immuni...
    ...duction in sedation during the,early post-operativ...gnificant reduction in nausea in the female,patien... 8th June 2007 - CeNeS Pharmaceuticals plc (AIM:,C..., announces,additional data from post-hoc analysis...rphine-6-glucuronide) in over 500 patients,with po...
    Other Medicine Technology:Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency 2Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency 3Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 2Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 3Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 4Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 5Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 6Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 7